Oragenics (OGEN) Total Non-Current Liabilities (2017 - 2023)
Oragenics' (OGEN) quarterly Total Non-Current Liabilities came in at $65752.0 in Q2 2023, down 69.75% YoY from $217353.0 in Q2 2022, and down 37.06% on a QoQ basis from $104463.0 in Q1 2023.
Oragenics (OGEN) Total Non-Current Liabilities (2017 - 2023) Analysis & Trends
Oragenics (OGEN) has 6 years of Total Non-Current Liabilities data on file, last reported at $65752.0 in Q2 2023.
- Quarterly Total Non-Current Liabilities fell 69.75% year-over-year to $65752.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $65752.0 (down 69.75% YoY) and the FY2022 annual result came in at $152439.0, down 49.11% from the prior year.
- Total Non-Current Liabilities eased to $65752.0 in Q2 2023, from $104463.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $670690.0 in Q4 2019 to a low of $65752.0 in Q2 2023.
- A 5-year average of $388803.8 and a median of $398177.0 in 2021 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2020 — Total Non-Current Liabilities dropped 5.24% — and 2023, when it tumbled 69.75%.
- Tracing OGEN's Total Non-Current Liabilities over 5 years: stood at $670690.0 in 2019, then dropped by 26.38% to $493790.0 in 2020, then sank by 39.34% to $299520.0 in 2021, then slumped by 49.11% to $152439.0 in 2022, then plunged by 56.87% to $65752.0 in 2023.
- The last three Total Non-Current Liabilities figures came in at $65752.0 (Q2 2023), $104463.0 (Q1 2023), and $152439.0 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 65,752.00 |
| Mar 31, 2023 | 104,463.00 |
| Dec 31, 2022 | 152,439.00 |
| Sep 30, 2022 | 204,593.00 |
| Jun 30, 2022 | 217,353.00 |
| Mar 31, 2022 | 253,928.00 |
| Dec 31, 2021 | 299,520.00 |
| Sep 30, 2021 | 349,199.00 |
| Jun 30, 2021 | 398,177.00 |
| Mar 31, 2021 | 446,464.00 |
| Dec 31, 2020 | 493,790.00 |
| Sep 30, 2020 | 539,381.00 |
| Jun 30, 2020 | 583,866.00 |
| Mar 31, 2020 | 627,723.00 |
| Dec 31, 2019 | 670,690.00 |
| Sep 30, 2019 | 586,170.00 |
| Jun 30, 2019 | 616,157.00 |
| Sep 30, 2017 | 2.40 Mn |
| Jun 30, 2017 | 2.99 Mn |